These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 1705407

  • 21. The biophysics of sickle cell hydroxyurea therapy.
    Eaton WA, Hofrichter J.
    Science; 1995 May 26; 268(5214):1142-3. PubMed ID: 7539154
    [No Abstract] [Full Text] [Related]

  • 22. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM, Wakamb GK, Mulangu AM, Nkashama GM, Kupa BK, Numbi OL.
    Pan Afr Med J; 2015 May 26; 21():124. PubMed ID: 26327961
    [Abstract] [Full Text] [Related]

  • 23. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM, Taher AT, Cappellini MD, Sankaran VG.
    Blood; 2013 Mar 21; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [Abstract] [Full Text] [Related]

  • 24. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
    Vasavda N, Badiger S, Rees D, Height S, Howard J, Thein SL.
    Br J Haematol; 2008 Nov 21; 143(4):589-92. PubMed ID: 18764867
    [Abstract] [Full Text] [Related]

  • 25. Sickle cell disease severity: an introduction.
    Pace BS, Goodman SR.
    Exp Biol Med (Maywood); 2016 Apr 21; 241(7):677-8. PubMed ID: 27190296
    [No Abstract] [Full Text] [Related]

  • 26. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
    Dover GJ, Charache S, Boyer SH.
    Trans Assoc Am Physicians; 1984 Apr 21; 97():140-5. PubMed ID: 6085527
    [No Abstract] [Full Text] [Related]

  • 27. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE, BABY HUG Investigators.
    Am J Hematol; 2013 Jul 21; 88(7):571-6. PubMed ID: 23606168
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.
    Stamatoyannopoulos JA, Nienhuis AW.
    Annu Rev Med; 1992 Jul 21; 43():497-521. PubMed ID: 1374600
    [Abstract] [Full Text] [Related]

  • 29. [Fetal hemoglobin].
    Rokicka-Piotrowicz M.
    Postepy Hig Med Dosw; 1989 Jul 21; 43(5-6):475-97. PubMed ID: 2484927
    [Abstract] [Full Text] [Related]

  • 30. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, Papachatzopoulou A, Kourakli A, Stavrou EF, Christou S, Hou J, Karkabouna S, Lappa-Manakou C, Ozgur Z, van Ijcken W, von Lindern M, Grosveld FG, Georgitsi M, Kleanthous M, Philipsen S, Patrinos GP.
    Pharmacogenomics; 2012 Oct 21; 13(13):1487-500. PubMed ID: 23057549
    [Abstract] [Full Text] [Related]

  • 31. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
    Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG.
    J Clin Invest; 1984 Aug 21; 74(2):652-6. PubMed ID: 6205021
    [Abstract] [Full Text] [Related]

  • 32. Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.
    Yang YM, Pace B.
    Pediatr Pathol Mol Med; 2001 Aug 21; 20(1):87-106. PubMed ID: 12673846
    [Abstract] [Full Text] [Related]

  • 33. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Aug 21; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 34. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM, Ebert BL.
    Expert Rev Hematol; 2012 Jun 21; 5(3):303-11. PubMed ID: 22780210
    [Abstract] [Full Text] [Related]

  • 35. Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy.
    Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.
    Eur J Haematol; 1996 May 21; 56(5):326-8. PubMed ID: 8641410
    [No Abstract] [Full Text] [Related]

  • 36. An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.
    Figueiredo L, Morrone K, Wei C, Ireland K, Cohen HW, Driscoll C, Manwani D.
    Blood Cells Mol Dis; 2017 Jul 21; 66():19-23. PubMed ID: 28783617
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.